Vitasora Health Launches vCare Platform With Enrolments Already Up 130%
vCare goes live — and enrolments are already accelerating
Vitasora Health Limited (ASX: VHL) has confirmed its proprietary vCare Electronic Medical Record (EMR) platform went live on 1 April 2026, delivering on milestones outlined in the company’s March quarterly report. The operational update, released on 15 May 2026, details a clear acceleration in patient enrolments, material cost savings from the platform transition, and a defined pathway to cashflow breakeven in the second half of calendar year 2026.
The vCare platform is now fully operational across the Chronic Care Management (CCM) business, transitioning patient workflows onto a unified system designed to improve enrolment efficiency, workforce flexibility, and reimbursement integrity. Management’s ability to execute on time against its own publicly stated targets reinforces the credibility of the forward-looking breakeven trajectory.
The Remote Patient Monitoring (RPM) module within vCare has been completed and is undergoing final live operational testing. Its commercial launch is expected from 1 July 2026, timed deliberately to align with full client reimbursement cycles and mitigate data risk during the transition from the legacy Ceras platform.
Enrolment momentum snaps higher
The platform transition has directly catalysed a meaningful uplift in patient onboarding. Key enrolment metrics from the update include:
- February/March 2026: Baseline period, with enrolments deliberately moderated during platform optimisation
- April 2026: 469 patients enrolled, almost double the February/March monthly average
- May month-to-date (first 7 billing days): 163 enrolments, implying a monthly run-rate exceeding 550 patients
- Growth rate: More than 130% versus the February/March baseline
- Addressable pipeline: Approximately 40,000 patients from existing contracted clients now in an active enrolment acceleration phase
The enrolment run-rate is the lead revenue driver. As the per-patient revenue model in the following section illustrates, each incremental patient enrolled translates directly into recurring monthly revenue.
When big ASX news breaks, our subscribers know first
The numbers behind the growth — cost savings meet revenue leverage
Platform economics — a >90% SaaS cost reduction
The transition from Ceras to the proprietary vCare platform delivers a substantial reduction in per-patient software costs. From July 2026, Vitasora expects to realise the full financial benefit of this shift.
| Metric | Legacy Ceras Cost | vCare Cost | Saving per Patient/Month | Annualised Saving (per 10,000 Patients) |
|---|---|---|---|---|
| SaaS cost per patient/month | ~US$7 | <US$1 | >US$6 | ~US$720K (A$1.05M) |
| Workflow automation & operational efficiencies | — | — | — | ~US$1.0M annualised |
| Total expected annualised savings | — | — | — | ~US$1.7–1.8M (A$2.4–2.6M) |
The SaaS cost reduction alone represents a greater than 90% decrease in per-patient platform expenditure. Combined with approximately US$1M in annualised operational efficiencies from workflow automation, improved workforce utilisation, and reduced reliance on third-party platforms, the total saving profile is expected to materially improve operating leverage as patient volumes scale.
Revenue scaling — what patient numbers mean in dollars
The per-patient revenue model gives investors a clear framework for tracking the financial impact of enrolment growth:
- Every 1,000 additional active patients is expected to generate approximately US$70,000–US$120,000 in monthly revenue, depending on care mix and reimbursement pathways.
- Average Fee-for-Service (FFS) revenue is approximately US$85 per patient per month.
- The current billed FFS patient base stands at approximately 2,800 patients.
- Reaching approximately 6,500 billed FFS patients would support monthly FFS revenue of approximately US$550K.
- Combined with existing UPEC (Call Centre services) and TCM/PMPM revenue streams, this would represent an estimated monthly revenue run-rate of approximately US$650K, which management identifies as the forecast business-as-usual profitability threshold.
The gap between the current 2,800 patients and the 6,500 target is the central investment thesis. With enrolment momentum now running at an implied rate exceeding 550 patients per month, the trajectory toward this threshold is becoming quantifiable.
What is Chronic Care Management — and why does the US reimbursement model matter?
Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) are US federal programmes that allow healthcare providers to bill Medicare’s Centres for Medicare and Medicaid Services (CMS) for the ongoing care of patients with chronic conditions outside of traditional clinic visits. Providers deliver structured care coordination and remote health monitoring to eligible patients, who are enrolled into these programmes on an ongoing basis.
CMS reimburses providers on a per-patient, per-month basis under a Fee-for-Service model. This means that once a patient is enrolled and active, they generate a recurring monthly revenue stream for as long as they remain in the programme. For a company like Vitasora, this structure means enrolment numbers translate almost directly into predictable, recurring revenue.
Platform transitions carry reimbursement risk because billing accuracy depends on data integrity between the clinical platform and CMS billing cycles. Vitasora’s decision to stage the RPM module launch to 1 July 2026, aligning with full client reimbursement cycles, reflects a deliberate strategy to protect revenue continuity for its clients during the transition period. Investors should understand that this was a risk management decision, not a setback.
The next major ASX story will hit our subscribers first
Collections improve and cashflow breakeven in sight
Alongside the enrolment acceleration, Vitasora has reported meaningful progress in cash collections since the close of the March quarter. Key metrics include:
- Accounts receivable at 31 March 2026: US$990K
- Collected post-quarter (by mid-May 2026): approximately US$490K
- 60+ day receivables reduced: approximately 30% versus the March ageing profile
- 90+ day receivables reduced: approximately 40% versus the March ageing profile
- Management remains confident in the recoverability of the remaining receivable balance
- Target: monthly business-as-usual cashflow breakeven in H2 CY2026
The improvement in debtor ageing reflects stronger collection performance and increasing operational discipline across the business.
CEO & Managing Director Marjan Mikel
“The successful implementation of vCare marks a transformational milestone for Vitasora. Importantly, we have now executed on the operational initiatives outlined in our March Quarterly update and are already seeing tangible acceleration in patient onboarding activity. The completion of the RPM module positions us to fully transition from legacy systems while maintaining reimbursement integrity and continuity for our clients. Early enrolment trends are encouraging and reinforce management’s confidence in the scalability of the platform, the strength of demand from our existing client base and our pathway toward sustainable operational cashflow generation.”
With the RPM module commercial launch scheduled for 1 July 2026 and enrolment acceleration already tracking well above the February/March baseline, investors will be watching two near-term catalysts closely: the July RPM go-live and ongoing monthly enrolment data as the company progresses toward its H2 CY2026 breakeven target.
Don’t Miss the Next ASX Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 subscribers rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.